non-invasive-diagnostics
(7)
Cleerly
Cleerly is a Denver-based digital healthcare company using FDA-cleared artificial intelligence to analyze coronary CT scans and non-invasively measure plaque, stenosis and the likelihood of ischemia in the heart's arteries. Founded in 2017 by cardiologist James K. Min, the company builds machine-learning software that turns a routine CCTA scan into a quantitative, vessel-by-vessel picture of coronary artery disease - aiming to catch atherosclerosis earlier and help physicians prevent heart attacks rather than react to them.
Pearl Diagnostics, Inc.
Pearl Diagnostics is a Baltimore-based in vitro diagnostics company spun out of Johns Hopkins University that develops non-invasive urine tests to detect life-threatening lung infections. Its proprietary Smart Antibody technology identifies circulating microbial extracellular vesicles, and its lead product, the MycoMEIA Aspergillus Assay, became the first urine-based test to win FDA 510(k) clearance for aiding diagnosis of invasive aspergillosis. The company raised an $11.2M Series A in March 2026 to commercialize in the US and expand across Europe.
Eric Gornstein
Eric Gornstein is the Chief Executive Officer of Pearl Diagnostics, a Johns Hopkins spinout in Baltimore that makes MycoMEIA, the first FDA-cleared urine test for invasive aspergillosis. A biopharma commercialization veteran with more than 25 years leading product launches, partnering and deal-making across therapeutic areas, he joined Pearl in late 2025 to take the company from FDA clearance to the market and into Europe. Earlier he helped launch Radius Health's first product, Tymlos, and worked in business development and cell therapy partnerships at companies including bit.bio and Talaris Therapeutics.
Heartflow
Heartflow is a Silicon Valley medical technology company that uses AI and computational fluid dynamics to turn a standard coronary CT scan into a personalized, color-coded 3D model of a patient's heart. Its FFRCT, Plaque and RoadMap analyses help cardiologists diagnose and manage coronary artery disease non-invasively, reducing the need for invasive angiograms. Founded in 2007 and headquartered in San Francisco, Heartflow has analyzed hundreds of thousands of patients across more than 1,500 U.S. hospitals and went public on the Nasdaq (HTFL) in August 2025.
Shlomi Madar
Shlomi Madar is the CEO of SpotitEarly, an Englewood, New Jersey biotech developing a non-invasive, breath-based multi-cancer screening test that pairs trained scent-detection dogs with a deep-learning platform. He holds a PhD in cancer research from the Weizmann Institute of Science and has spent more than fifteen years in life sciences and healthcare, previously serving as VP of Strategic Alliances at OncoHost and working on the Weizmann Institute's innovation arm. In May 2025 SpotitEarly closed a $20.3M Series A behind clinical results the company reports at roughly 94% sensitivity and specificity across four cancer types.
G-Tech Medical
G-Tech Medical builds the GutTracker, a thin wireless wearable patch its team calls an 'EKG for the Gut.' Worn on the abdomen for up to six days at home, the patch reads the faint electrical signals that drive the stomach, small intestine, and colon, then streams them over Bluetooth to the cloud, where algorithms turn the noise into patient-specific motility data. The Mountain View company aims to replace short, single-organ, in-clinic tests with continuous, whole-gut measurement so physicians can finally see how a digestive system actually behaves day to day.
Superfluid Dx, Inc.
Superfluid Dx is a South San Francisco diagnostics company building a blood-based test for Alzheimer's disease and other neurodegenerative conditions. Its platform isolates cell-free messenger RNA (cf-mRNA) from a single tube of blood and pairs next-generation sequencing with RNA deconvolution and machine-learning analysis to read out organ-level biology - aiming to detect disease years earlier than conventional methods and to guide therapy. The company was formed in late 2023 when WRQ Sciences acquired and renamed Molecular Stethoscope, and is led by Fluidigm co-founder Gajus Worthington alongside Stanford bioengineer and serial founder Steve Quake.